6CM
SMMT icon

683 Capital Management’s Summit Therapeutics SMMT Stock Holding History

683 Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,838
Closed -$216K – 325
2022
Q4 		$216K Buy
+50,838
New +$92.5K 0.02% 152

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

683 Capital Management's SMMT Position: Q1 2023 in Review

683 Capital Management sold out of Summit Therapeutics (SMMT) in Q1 2023, closing a stake of 50,838 shares — an estimated $216K sold.

683 Capital Management first reported a position in SMMT in Q4 2022 and held it in 1 quarter. The position peaked at $216K in Q4 2022. 91 funds tracked by Wall St. Rank hold SMMT as of Q1 2023.

  • 683 Capital Management reported no remaining Summit Therapeutics position as of Q1 2023 after selling out during the quarter.
  • 683 Capital Management sold 50,838 Summit Therapeutics shares in Q1 2023, an estimated $216K.
  • 683 Capital Management first reported a position in Summit Therapeutics in Q4 2022 and held it in 1 quarter.
  • 683 Capital Management's Summit Therapeutics position peaked at $216K in Q4 2022.
  • 91 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2023.

Based on 683 Capital Management's 13F filing for Q1 2023, filed 15 May 2023.